CAJ | 학술논문

目的：比较乳腺癌TAC方案化疗后，应用聚乙二醇化重组人粒细胞刺激因子和人粒细胞刺激因子预防粒细胞减少的临床疗效。方法：选取2013年1-8月入院接受TAC方案化疗的乳腺癌患者共60例。30例为试验组，化疗结束后48 h给予聚乙二醇化重组人粒细胞刺激因子（PEG-rhG-CSF）；30例为对照组，化疗结束后48 h给予重组人粒细胞刺激因子（rhG-CSF）。结果：试验组化疗间歇期中性粒细胞减少、感染病例明显少于对照组，差异有统计学意义（P<0.05）。结论：乳腺癌TAC方案化疗后应用聚乙二醇化重组人粒细胞刺激因子预防中性粒细胞减少疗效确切，值得临床推广应用。
목적：비교유선암TAC방안화료후，응용취을이순화중조인립세포자격인자화인립세포자격인자예방립세포감소적림상료효。방법：선취2013년1-8월입원접수TAC방안화료적유선암환자공60례。30례위시험조，화료결속후48 h급여취을이순화중조인립세포자격인자（PEG-rhG-CSF）；30례위대조조，화료결속후48 h급여중조인립세포자격인자（rhG-CSF）。결과：시험조화료간헐기중성립세포감소、감염병례명현소우대조조，차이유통계학의의（P<0.05）。결론：유선암TAC방안화료후응용취을이순화중조인립세포자격인자예방중성립세포감소료효학절，치득림상추엄응용。
Objective:To compare the effect of the application of polyethylene glycol(peg)recombinant human granulocyte stimulating factor and recombinant human granulocyte stimulating factor to prevent granulocytopenia after TAC scheme chemotherapy. Method:60 cases of breast cancer treated by TAC scheme chemotherapy from January 2013 to August 2013 hospitalized were randomly divided into two groups. The experimental group was treated with the polyethylene glycol recombinant human granulocyte stimulating factor(PEG-rhG CSF)after the end of the chemotherapy for 48 hours.The control group was treated with recombinant human granulocyte stimulating factor(rhG CSF)after the end of the chemotherapy for 48 hours.Result:The case of neutropenia and infection of experimental group in chemotherapy intermission were obviously less than that of the control group,there was statistical significance(P<0.05).Conclusion:The curative effect of polyethylene glycol(peg)of recombinant human granulocyte stimulating factor injection in preventing breast cancer TAC scheme post-chemotherapy neutropenia is good,and is worth to be widely applied in clinical.